Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

 

 

Webcasts

08-10-2020

Reata Pharmaceuticals Second Quarter Financial Results and Update on Development Programs

Webcast: click here

Teleconference Information

Date: Monday, August 10, 2020
Time: 08:30 am ET
Audience Dial-in (toll-free): (800) 708-4539
Audience Dial-in (international): (847) 619-6396
Access Code: 49873533

06-11-2020

Reata Pharmaceuticals and Blackstone Life Sciences Announce $350 Million Strategic Investment

Webcast: click here

Press (06-11-2020): 
Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment

Teleconference Information

Date: Thursday, June 11, 2020
Time: 08:30 am ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 3371798

Read more
 MP3

05-11-2020

Reata Pharmaceuticals First Quarter Financial Results and Update on Development Programs

Webcast: click here

Press (05-11-2020): 
Reata Pharmaceuticals, Inc. Announces First Quarter 2020 Financial Results and Provides an Update on Development Programs

Press (05-04-2020): 
Reata Pharmaceuticals, Inc. to Report First Quarter 2020 Financial Results and to Provide an Update on Development Programs on May 11, 2020

Teleconference Information

Date: Monday, May 11, 2020
Time: 04:30 pm ET
Audience Dial-in (toll-free): (844) 348-3946
Audience Dial-in (international): (213) 358-0892
Access Code: 6936548

Read more
 MP3
 PDF

Events and Presentations

06-11-2020

Corporate Presentation

 PDF

06-07-2020

2020 ERA-EDTA Posters

Poster: Colin J. Meyer, M.D., Reata Pharmaceuticals, European Renal Association–European Dialysis and Transplant Association, Milan, Italy, presented Kidney Effects in the MOXIeTrial: A Study of Omaveloxolone in Patients with Friedreich’s Ataxia

Poster: Prasad Devarajan, M.D., Reata Pharmaceuticals Consultant, European Renal Association–European Dialysis and Transplant Association, Milan, Italy, presented KIDNEYCODE: A Genetic Testing Program for Patients with Chronic Kidney Disease

Poster: R.J. White, MD, Ph.D., Reata Pharmaceuticals Investigator, European Renal Association–European Dialysis and Transplant Association, Milan, Italy, presented Application of a Risk-Mitigation Strategy to Prevent Excess Heart Failure Risk in Pulmonary Hypertension: LARIAT Study

Read more
 PDF

11-10-2019

2019 ASN Posters

Poster: C. Wanner, M.D., University Hospital Würzburg, Würzburg, Germany presented Effect of Bardoxolone Methyl on Kidney Events in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes at High Risk of Adverse Kidney Outcomes

Poster: P.E. Pergola M.D., Ph.D. Renal Associates, San Antonio, TX, USA presented A Cardiovascular Risk Mitigation Strategy on the Safety of Bardoxolone Methyl Post-BEACON

Read more
 PDF
 PDF

10-18-2019

CNBC Interviews Reata CEO Warren Huff

Video Thumbnail
Reata CEO on positive trial results for drug to treat Friedreich's ataxia

Vineet Jindal

Vineet Jindal

Vice President, Corporate
Communications & Strategy

 (855) 55-REATA